I figure that we'll need to spend about $192 million starting today to get to FDA approval: $4 million per month for 48 months. Subtract around $20 million cash on hand currently, $37 million from reimbursements for DurAVR's used in trials, $57 million in options that can be converted at $29 and around 2.7 million options at an average of maybe 10 bucks. That means we'll need another $51 million to get to approval if everything goes reasonably well, although cash burn could increase during the pivotal trial.
My projection has been that we'll wind up with somewhere around 25 million shares fully diluted or less when we sell our first valve post-approval and that seems reasonable as we currently have less than 21 million shares fully diluted.
- Forums
- ASX - By Stock
- AVR
- Ann: DurAVR Maintains Exceptional Results in New Patient Cohort
Ann: DurAVR Maintains Exceptional Results in New Patient Cohort, page-14
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$19.81 |
Change
0.260(1.33%) |
Mkt cap ! $380.7M |
Open | High | Low | Value | Volume |
$19.55 | $20.50 | $19.50 | $457.3K | 22.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 300 | $19.77 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.81 | 978 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 300 | 19.770 |
1 | 500 | 19.750 |
2 | 1035 | 19.300 |
2 | 1500 | 19.200 |
1 | 500 | 19.100 |
Price($) | Vol. | No. |
---|---|---|
19.810 | 978 | 2 |
20.000 | 851 | 2 |
20.500 | 1930 | 1 |
20.750 | 150 | 1 |
21.000 | 250 | 1 |
Last trade - 16.10pm 21/05/2024 (20 minute delay) ? |
|
|||||
Last
$20.10 |
  |
Change
0.260 ( 2.71 %) |
|||
Open | High | Low | Volume | ||
$19.99 | $20.10 | $19.91 | 302 | ||
Last updated 12.44pm 21/05/2024 ? |
Featured News
AVR (ASX) Chart |
The Watchlist
AUQ
ALARA RESOURCES LIMITED
Stephen Gethin, Non-Executive Director & Chairman
Stephen Gethin
Non-Executive Director & Chairman
Previous Video
Next Video
SPONSORED BY The Market Online